JP7842752B2 - 骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物 - Google Patents

骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物

Info

Publication number
JP7842752B2
JP7842752B2 JP2023527016A JP2023527016A JP7842752B2 JP 7842752 B2 JP7842752 B2 JP 7842752B2 JP 2023527016 A JP2023527016 A JP 2023527016A JP 2023527016 A JP2023527016 A JP 2023527016A JP 7842752 B2 JP7842752 B2 JP 7842752B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
flt3
leukemia
composition according
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023527016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548190A5 (https=
JP2023548190A (ja
Inventor
ファン ベ，イン
ヨン ソン，ジ
ユル チェ，ジェ
ギル アン，ヨン
Original Assignee
ハンミ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンミ ファーマシューティカル カンパニー リミテッド filed Critical ハンミ ファーマシューティカル カンパニー リミテッド
Publication of JP2023548190A publication Critical patent/JP2023548190A/ja
Publication of JP2023548190A5 publication Critical patent/JP2023548190A5/ja
Application granted granted Critical
Publication of JP7842752B2 publication Critical patent/JP7842752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023527016A 2020-11-05 2021-11-03 骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物 Active JP7842752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0147156 2020-11-05
KR20200147156 2020-11-05
PCT/KR2021/015794 WO2022098083A1 (ko) 2020-11-05 2021-11-03 Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
JP2023548190A JP2023548190A (ja) 2023-11-15
JP2023548190A5 JP2023548190A5 (https=) 2024-11-12
JP7842752B2 true JP7842752B2 (ja) 2026-04-08

Family

ID=81458079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527016A Active JP7842752B2 (ja) 2020-11-05 2021-11-03 骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物

Country Status (8)

Country Link
US (1) US20260102397A1 (https=)
EP (1) EP4241773A4 (https=)
JP (1) JP7842752B2 (https=)
KR (1) KR20220061026A (https=)
CN (1) CN116583284A (https=)
CA (1) CA3197836A1 (https=)
TW (1) TW202233193A (https=)
WO (1) WO2022098083A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
CN117586344B (zh) * 2022-08-12 2025-07-25 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527128A (ja) 2018-07-25 2020-09-03 ハンミ ファーマシューティカルズ カンパニー リミテッド ピリミジン化合物、及びそれを含む癌の予防用または治療用の薬学組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN110229142A (zh) * 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
KR102110573B1 (ko) * 2015-08-13 2020-05-13 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
KR20200102948A (ko) * 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527128A (ja) 2018-07-25 2020-09-03 ハンミ ファーマシューティカルズ カンパニー リミテッド ピリミジン化合物、及びそれを含む癌の予防用または治療用の薬学組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
British Journal of Cancer，2020年02月04日，122，pp.1175-1184，DOI: 10.1038/s41416-020-0731-z

Also Published As

Publication number Publication date
EP4241773A1 (en) 2023-09-13
KR20220061026A (ko) 2022-05-12
JP2023548190A (ja) 2023-11-15
CA3197836A1 (en) 2022-05-12
WO2022098083A1 (ko) 2022-05-12
EP4241773A4 (en) 2024-10-16
CN116583284A (zh) 2023-08-11
US20260102397A1 (en) 2026-04-16
TW202233193A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
JP7842752B2 (ja) 骨髄性白血病の治療のためのｆｌｔ３阻害剤を含む医薬組成物
US20220241277A1 (en) Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
EP2791101B1 (en) Treatment of non-alcoholic steatohepatitis
EP3038652B1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
UA125216C2 (uk) Комбінована терапія
EA019064B1 (ru) Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа
US20110021524A1 (en) Compositions and methods for treating cancers
TW202031253A (zh) 治療黑色素瘤的藥物組合
EA029718B1 (ru) Бифтордиоксалан-аминобензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
JP2022521380A (ja) Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
JP2009543874A (ja) チアゾリジノン誘導体
AU2017245332A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
US20050075358A1 (en) Methods for treating IGF1R-inhibitor induced hyperglycemia
HK40102115A (en) Pharmaceutical composition for treating leukemia comprising flt3 inhibitor
US10196378B2 (en) Inhibitors of BCR-ABL mutants and use thereof
CN117479943A (zh) 组合疗法中的egfr抑制剂和perk活化剂及其用于治疗癌症的用途
US20120283303A1 (en) Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
Bunting et al. Blood First Edition Paper, prepublished online July 17, 2012; DOI 10.1182/blood-2011-08-375873
HK40066928A (zh) 用於治疗癌症的组合物和方法
HK1199015B (en) Treatment of non-alcoholic steatohepatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260327

R150 Certificate of patent or registration of utility model

Ref document number: 7842752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150